A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)

被引：0
|
作者：
Valero, I. Perez [1 ]
Llibre, J. M. [2 ]
Lazzarin, A. [3 ]
Di Perri, G. [4 ]
Pulido, F. [5 ]
Molina, J. -M. [6 ,7 ]
Esser, S. [8 ]
McNicholl, I. [9 ]
Lorgeoux, R. -P. [10 ]
Margot, N. [9 ]
Shao, Y. [9 ]
Piontkowsky, D. [9 ]
Das, M. [9 ]
Haubrich, R. [9 ]
机构：
[1] Hosp Univ La Paz, Unidad VIH, Madrid, Spain
[2] Fdn Lucha SIDA, Barcelona, Spain
[3] Fdn IRCCS San Raffaele Monte Tabor, Milan, Italy
[4] Dipartimento Malattie Infett & Trop, Turin, Italy
[5] UCM, Hosp Univ Octubre 12, Imas12, Unidad VIH, Madrid, Spain
[6] St Louis Hosp, Dept Infect Dis, Paris, France
[7] Univ Paris, Paris, France
[8] Univ Klinikum Essen, Essen, Germany
[9] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[10] Gilead Sci Inc, Montreal, PQ, Canada
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
TUAB0104
引用
收藏
页码：6 / 7
页数：2
相关论文
共 8 条
  • [1] A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring NRTI resistance mutations M184V/I +/- TAMs (GS-US-292-1824): week 24 results
    Perez-Valero, I.
    Llibre, J. M.
    Lazzarin, A.
    Di Perri, G.
    Pulido, F.
    Molina, J-M
    Esser, S.
    Margot, N.
    Shao, Y.
    Piontkowsky, D.
    Das, M.
    McNicholl, I.
    Haubrich, R.
    [J]. HIV MEDICINE, 2019, 20 : 170 - 171
  • [2] A phase 3b open-label pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single tablet regimen (STR) in virologically suppressed HIV-1 infected adults harbouring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)
    Perez-Valero, I.
    Llibre, J. M.
    Pulido, F.
    Molina, J-M
    Esser, S.
    McNicholl, I.
    Lorgeoux, R-P
    Piontkowsky, D.
    Sathia, L.
    Haubrich, R.
    [J]. HIV MEDICINE, 2018, 19 : S21 - S21
  • [3] Phase IIIb, randomized, open-label study to evaluate switching from a tenofovir disoproxil fumarate (TDF)-containing regimen to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed, HIV-1 infected participants aged ≥60
    Maggiolo, F.
    Rizzardini, G.
    Raffi, F.
    Pulido, F.
    Mateo Garcia, G.
    Molina, J.
    Ong, E.
    Shao, Y.
    Corales, R.
    McNicholl, I.
    Piontkowsky, D.
    Das, M.
    Haubrich, R.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [4] A retrospective analysis to evaluate and compare the efficacy of switching to Stribild fixed-dose combination in virologically suppressed HIV-1 infected adults with or without the archived NRTI resistance mutation M184V/I
    Silebi, Vanessa
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [5] Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial
    Kityo, Cissy
    Hagins, Debbie
    Koenig, Ellen
    Avihingsanon, Anchalee
    Chetchotisakd, Ploenchan
    Supparatpinyo, Khuanchai
    Gankina, Natalya
    Pokrovsky, Vadim
    Voronin, Evgeny
    Stephens, Jeffrey L.
    DeJesus, Edwin
    Wang, Hui
    Acosta, Rima K.
    Cao, Huyen
    Quirk, Erin
    Martin, Hal
    Makadzange, Tariro
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 82 (03) : 321 - 328
  • [6] Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
    Maggiolo, Franco
    Rizzardini, Giuliano
    Raffi, Francois
    Pulido, Federico
    Gracia Mateo-Garcia, Maria
    Molina, Jean-Michel
    Ong, Edmund
    Shao, Yongwu
    Piontkowsky, David
    Das, Moupali
    McNicholl, Ian
    Haubrich, Richard
    [J]. LANCET HIV, 2019, 6 (10): : E655 - E666
  • [7] A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naive, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
    Iwuji, Collins C.
    Churchill, Duncan
    Bremner, Stephen
    Perry, Nicky
    To, Ye
    Lambert, Debbie
    Bruce, Chloe
    Waters, Laura
    Orkin, Chloe
    Geretti, Anna Maria
    [J]. BMC INFECTIOUS DISEASES, 2020, 20 (01)
  • [8] A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
    Collins C. Iwuji
    Duncan Churchill
    Stephen Bremner
    Nicky Perry
    Ye To
    Debbie Lambert
    Chloe Bruce
    Laura Waters
    Chloe Orkin
    Anna Maria Geretti
    [J]. BMC Infectious Diseases, 20
1